1 – 5 of 8
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Detailed Long-Term Follow-Up of Patients Who Relapsed after the Nordic Mantle Cell Lymphoma Trials : MCL2 and MCL3
(
- Contribution to journal › Article
- 2017
-
Mark
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
(
- Contribution to journal › Article
- 2015
-
Mark
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase 2 study by The Nordic Lymphoma Group.
(
- Contribution to journal › Article
- 2014
-
Mark
Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
(
- Contribution to journal › Article
- 2012
-
Mark
Upfront Autologuos Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01.
(
- Contribution to journal › Article